1. Introduction {#s0005}
===============

Mucinous ovarian carcinoma (mOC) is a complex group of tumors frequently associated within a single "malignant" ovarian disease. These tumors exhibit varying transitional histologic patterns that include benign cystadenoma, borderline patterns, and invasive disease ([@bb0025]; [@bb0030]; [@bb0065]). Within the last four decades, different classifications of mucinous tumors have been described ([@bb0025]; [@bb0030]; [@bb0065]; [@bb0015]). Conventionally, the cut-off between borderline and malignant ovarian tumors is based on the absence/presence of "frank" stromal invasion. In 2000, Lee and Scully introduced the expansile and infiltrative types of mOC based on morphological and prognostic differences ([@bb0030]). In 2014, the WHO proposed to standardize pathological reports of mOC (and also borderline disease) by classifying primary mucinous cancers as expansile or infiltrative, according to the growth pattern ([@bb0025]). The expansile type has a better prognosis than the infiltrative type ([@bb0030]). Nevertheless, to our knowledge, only one previous study (which included 44 cases) specifically addressed the value of peritoneal and nodal staging surgery for the expansile and infiltrative types of mOC.

2. Patients and methods {#s0010}
=======================

We retrospectively identified patients with mOC that were referred or treated in our institution between 1976 and 2016. Patients were included when they met the following inclusion criteria:1.Sufficient data available for a centralized pathologic review of the ovarian tumors, performed by two expert pathologists (CG and MDS), according to the 2014 WHO classification guidelines ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}). Patients were excluded when data on the initial ovarian tumor were not available for pathologic review (i.e., for patients treated outside our institution or for some of the oldest cases).Fig. 1Morphology of infiltrative mucinous carcinoma (hematoxylin-eosin-safran staining × 200).Fig. 1Fig. 2Morphology of expansile mucinous carcinoma (hematoxylin-eosin-safran staining × 40).Fig. 22.Primary mOC; tumors that had metastasized to the ovaries were excluded.3.Macroscopic stage I disease only (no extra-ovarian disease identified in the surgical exploration).4.Sufficient surgical and histological data available to determine the precise surgical procedures carried out and their histologic results.

"Complete" peritoneal surgical staging was defined as, at minimum, the acquisition of peritoneal cytology, multiple peritoneal biopsies, and an omentectomy or omental biopsies. An appendectomy was not included in the minimum requirements for a "complete" staging surgery in this series. Similarly, lymph node resection and uterine curettage (in case of conservative surgery) were optional for a complete staging surgery. In some cases, ovarian tumor surgery and staging (when performed) were performed in a one-step surgery, when the malignancy could be diagnosed during the surgery with a frozen section analysis. In others cases, the staging surgery was performed in two steps (restaging surgery). These surgeries were carried out with laparoscopic or laparotomic approaches, according to the judgment of the surgical teams. A "radical" surgery was defined as the removal of both adnexae. Conservative surgery was defined as the preservation of at least part of one ovary and the uterus.

Tumors were typed as expansile or infiltrative, according to the 2014 WHO classification criteria ([@bb0025]). Clinical and histologic characteristics were studied for both histotypes. According to consensus, the grading system used for serous cancers is not applicable to mucinous subtypes. The 2014 WHO classification does not include recommendations about tumor grading in mOC. Thus, in the present series, for expansile subtype, we implemented the nuclear grading system recommended by Rodriguez & Prat ([@bb0065]).

We evaluated the value of peritoneal (and nodal) staging procedures, based on the rate of microscopic involvement histologically determined for macroscopically normal specimens. The 2014 International Federation of Gynecology and Obstetrics (FIGO) staging system was implemented; in particular, this system included 3 new classes of stage IC disease ([@bb0060]). According to local regulation, no IRB was required in such retrospective study.

3. Results {#s0015}
==========

We reviewed 114 cases. Forty-six were excluded because the macroscopic disease severity was greater than stage I (n = 26 cases: 2 stage II, 18 stage III, 4 stage IV, and 2 unknown) or the lack of accessibility for a pathologic review (n = 20). The final analysis included 68 cases: 29 expansile and 39 infiltrative mOC types. The characteristics of the 68 patients are detailed in [Table 1](#t0005){ref-type="table"}.Table 1Characteristics of patients according to the type of mucinous tumor.Table 1CharacteristicExpansile n = 29Infiltrative n = 39Median age, years (range)40 (14--83)35 (16--78)Menopausal patients No1829 Yes56 Undetermined64Body mass index, kg/m^2^22 (19--34)23 (17--34)Previous history Borderline[a](#tf0005){ref-type="table-fn"}01 Cancer[b](#tf0010){ref-type="table-fn"}02Previous appendectomy1211Median tumor size (diameter), cm (range)14 (7--26)12 (4--30)Bilateral Yes11 No2636FIGO stage IA1322 IB00 IC199 IC257 IC321Nuclear grade Grade 111-- Grade 210-- Grade 30-- Undetermined8--[^1][^2][^3][^4]

The details of the surgical procedures are given in [Table 2](#t0010){ref-type="table"}. Twenty-seven patients underwent a one-step surgery, and 41 underwent a restaging surgery. Sixty-seven patients had data for at least peritoneal cytology during the initial and/or restaging surgery. "Complete" peritoneal surgical staging was carried out in 52 cases. Twenty-four patients underwent an appendectomy (23 others had a previous history of appendectomy). Lymphadenectomy was carried out in 31 patients (one patient received a pelvic lymphadenectomy alone); of these, 8 had expansile and 23 had infiltrative mOC. Twenty-seven of these lymphadenectomies were done during a restaging surgery. Before histologic analyses of the staging specimens, 35 patients had "initial" stage IA, and 33 had stage IC disease.Table 2Surgical procedures according to histologic type of mucinous carcinoma.Table 2ProcedureExpansile n = 29Infiltrative n = 39One-step surgery (ovary and staging procedures)1512 Laparotomy96 Laparoscopy10 Unknown56Two-step surgery1427 Median delay, months22 Laparotomy only614 Laparoscopy only11 Both procedures66 Unknown16Tumor rupture1413 Preoperative66 Perioperative86Conservative surgery Yes1215 No1724Peritoneal staging Cytology2938 Peritoneal biopsies2334 Omentectomy or omental biopsies2536 Appendectomy1014 Complete peritoneal staging2329Lymph node staging Pelvic only10 Pelvic and para-aortic723 Median number of nodes removed (range)28 (1--35)13 (2--63)[^5]

The histologic analyses demonstrated that three patients had isolated positive cytology. Of these, two were upstaged from stage IC1 (perioperative rupture) to IC3, and one was upstaged from macroscopic stage IA to IC3. Two exhibited the expansile mOC type. Two patients were treated with 2-step surgeries (1 exhibited positive cytology during the 1st surgery, and the other exhibited positive cytology during the restaging surgery). One patient received a one-step surgery.

After the histologic analysis of the peritoneal specimens, two patients exhibited microscopic peritoneal spread: one in the omentum, and the other in a random biopsy of the right diaphragm. After a histologic analysis of the lymph nodes, four patients had nodal involvement. The correlations between the initial stage, nuclear grade, and nodal status are detailed in [Table 3](#t0015){ref-type="table"}. All four of these patients had infiltrative mOC (4/23 that underwent lymphadenectomy: 17%). No nodal metastasis was observed among eight patients with expansile mOC that underwent lymph node sampling. Among the four patients with nodal spread, two had a single nodal metastasis (without capsular rupture); one was in the pelvic area, and one was in the para-aortic supra-mesenteric area. The third patient had 5 metastatic nodes (among 63 removed), all in para-aortic nodes (without capsular rupture). The fourth patient had pelvic and para-aortic nodal metastasis (number and size of nodes undetermined). Of these four patients, two also had microscopic peritoneal disease (patients previously described). The final FIGO staging classes of these patients were stages IIIA1 (n = 2) and IIIA2 (n = 2). No other case of microscopic peritoneal spread was observed. No appendiceal tumor was observed.Table 3Nodal status according to tumor stage (before analyzing staging specimens) and nuclear grade in expansile and infiltrative tumor types.Table 3Tumor characteristicsExpansile n = 8Infiltrative n = 23N −N +N −N +Disease stage (2014 FIGO classification) IA2--93 IC13--51 IC22--4-- IC31--1--Nuclear grade Grade 13------ Grade 25------ Grade 3--------[^6]

4. Discussion {#s0020}
=============

This study raised the complex issue of the value of peritoneal staging surgery, in terms of histologic detection rate (how many patients had histologic spread whereas macroscopic exploration is normal). We also investigated the question of how staging contributed to overall cancer management; we determined the percentage of patients that required adjuvant treatment, based only on the histologic results of staging surgery.

Among epithelial ovarian cancers, mOC is one of the least frequently observed. It can be characterized on the basis of 3 points: 1: It is diagnosed frequently in stage I (in contrast to other subtypes/3--5). 2: It is observed in younger patients, compared to the other types of ovarian cancer. 3: When observed at a more advanced stage, the prognosis is worse than that of the other types of ovarian cancer. A key issue in mOC is that characterization is crucial for the differentiation between a primary ovarian tumor and metastatic disease from a non-gynecologic primitive tumor.

Because mOC is frequently observed at a limited stage and in the youngest patients, the quality of the staging surgery is a key factor. On the other hand, this group of tumors involves different entities, and previous studies on the histologic classifications have provided widely variable results; consequently, it is difficult to compare the results from different series previously published on this topic. Many studies that investigated the value of staging surgery included a mixture of mOC types ([@bb0005]). Others studies that distinguished between the types were mainly focused on the histologic characteristics of the tumors, but not clinical management ([@bb0030]; [@bb0065]). The only study that discussed this topic was published by Muyldermans et al. They studied 44 mOC cases (including 20 with lymph node sampling) ([@bb0045]). However, that interesting paper did not focus on other staging procedures ([@bb0045]). Thus, the present study was the first that specifically focused on studying the different staging procedures for both histologic types of mOC.

The two most important strengths of this study are firstly the number of stage I mOC cases (collecting the largest number of stage I mOC with characterization of expansile and infiltrative types); and secondly the accuracy of the histological analysis. This quality is increased by conducting the pathologic review with expert pathologists that have considerable experience in gynecological tumors. This point is particularly a corner stone in series about mucinous ovarian diseases mixing different patterns inside the same tumor. In the current series, the pathologic review was conducted by two senior pathologists, both with substantial expertise in these diseases. The two weaknesses of this study are its retrospective nature (but that is the methodology of a vast majority of studies about rare tumors) and its length (nearly 40 years). But this last potential weakness has an impact mainly on the discrepancy of the pathologic analysis within 4 decades, that have been corrected with the centralization of pathologic review previously mentioned.

Two aspects of the staging surgery must be evaluated: the peritoneal procedures and the lymphadenectomy. First, the peritoneal staging procedures appeared to provide low value, because previous studies in "macroscopic" stage I ovarian cancers indicated that mucinous cancer had the lowest rate of extra-ovarian microscopic spread ([@bb0005]; [@bb0050]; [@bb0035]; [@bb0010]). The series of Lee et al. showed that, in eight cases of stage I disease that were upstaged to IIIA, no mucinous tumor was found (out of 92 cases included in the series) ([@bb0035]). In the series of Cho et al., which included 60 cancer cases, no patients were upstaged to stage II or III disease ([@bb0005]). However, in the series of Powless et al., all eight patients upstaged to stage III disease exhibited pelvic spread on the peritoneum (stage II) ([@bb0050]). However, only two of the eight in the latter series were mucinous tumors ([@bb0050]). Interestingly, in the series of Cho et al., five cases of mucinous tumors were upstaged to stage IC3 disease, solely on the basis of positive cytology ([@bb0005]). Thus, the question has arisen: Can we simply skip the staging (or restaging) surgery in mOC? This is a crucial question because, although these staging procedures have low morbidity risk when the malignancy is detected during surgery, in cases where the initial diagnosis is mistaken (either no frozen section analysis/FSA or false negative results), the question is whether to perform a new surgery for adequate staging. Our results suggested that, although the detection rate is low, microscopic peritoneal spread could be observed even during (re)staging surgery in cases of macroscopically normal peritoneal cavity. In the present series, three patients were upstaged to stage IC3 based on isolated positive cytology, and two exhibited microscopic involvement in the omentum and in a right diaphragm biopsy. In a recent study by Garcia-Soto et al., three mucinous cancers that were upstaged had spread to similar locations ([@bb0010]). Our two patients upstaged to stage III disease initially had the infiltrative tumor type. No extra-ovarian spread was found among expansile subtype tumors, but one patient exhibited isolated positive cytology. These results suggested that peritoneal staging surgery should be conducted, regardless of the type of mOC.

The second question concerns the need for a lymph node resection. For 15 years, we have known that, in mOC, the rate of nodal spread is very low in an apparent stage I tumor ([@bb0070]; [@bb0040]; [@bb0055]; [@bb0020]; [@bb0075]). Over the last 10 years, some authors have suggested omitting lymph node resections in staging procedures for mOC ([@bb0040]). However, a recent study by Muyldermans et al. found that, among 10 infiltrative mOC cases that underwent lymph node sampling, 4 exhibited nodal spread ([@bb0045]). That study was the first to analyze the lymph node spread specifically in both mOC subtypes. We found similar results in the present study. Among 31 patients that underwent lymphadenectomy (including pelvic and para-aortic lymphadenectomies), we found positive nodes in 4 out of 23 patients (17%) in the infiltrative group. Moreover, among these four patients, two exhibited peritoneal metastasis. In contrast, we found no nodal metastasis in the expansile group. These crucial results demonstrated that, although we might omit the lymphadenectomy in expansile mOC cases, this procedure is required for infiltrative mOC cases, during either the initial or the restaging surgery. Ideally, can we use a FSA to determine between both subtypes and to carry out the lymphadenectomy during a single-step surgery only in infiltrative cases? As mOC are frequently bulky tumors (sometimes \> 25 cm), mixing different histologic components (from benign cystadenoma, to borderline aspects, intra-epithelial carcinoma and frankly invasive patterns) accuracy of FSA to determine the degree of malignancy (borderline disease or cancer) in mucinous tumors is particularly complex and need expert pathologists. To ask furthermore to the pathologist to determine between expansile or infiltrative in case of mOC "confirmed" during FSA, is really challenging and impossible. No specific papers had been published about this specific point. So, pragmatically, if a (midline) laparotomic approach is used (due to the volume of the tumor) and FSA confirms a mOC during the primary surgery, lympadenectomy could be used (as the laparotomy done) in patient with no co-morbidity (obesity, previous history of vascular disease...). If a laparoscopic approach used to remove the ovarian tumor, we can wait the permanent histologic analysis to decide a potential secondary surgery (using a mini-invasive approach).

However, in truth, although we demonstrated the diagnostic value of the lymphadenectomy, we did not demonstrate its therapeutic value, as many of patients with infiltrative subtypes received an adjuvant treatment, whatever the lymph node status. This therapeutic effect of the lymph node resection itself in apparent stage I Ovarian Cancer remains currently an unsolved debate with endless discussions. Only a large randomized trial comparing systematic lymphadenectomy and no lymph node resection in exclusively macroscopic stage I disease, could theoretically answer to this important topic but its feasibility, according to the number of patients required, remains doubtful.
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[^1]: Data are the number of patients in each group, unless otherwise indicated.

[^2]: FIGO: International Federation of Gynecology and Obstetrics.

[^3]: Borderline mucinous.

[^4]: Breast cancer.

[^5]: Data are the number of patients in each group, unless otherwise indicated.

[^6]: N −, negative nodal metastasis; N +, positive nodal metastasis FIGO: International Federation of Gynecology and Obstetrics.
